Can one pill before breast surgery cut the need for morphine?
NCT ID NCT07804784
First seen Sep 04, 2026 ยท Last updated Sep 04, 2026
Summary
This trial tests whether a single 600 mg dose of gabapentin, taken one hour before breast cancer surgery, reduces the amount of morphine needed for pain afterward. Sixty women scheduled for elective breast surgery will be randomly assigned to receive either gabapentin or a placebo pill. Researchers will measure total morphine use during recovery and watch for side effects like drowsiness, nausea, and vomiting. The goal is to see if this simple pre-treatment can improve pain control and lower opioid use.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a single 600 mg oral dose of gabapentin given one hour before surgery
- What this could lead to
- If it works, a single pill before surgery could ease pain and cut the need for morphine, reducing opioid side effects.
- What could go wrong
- This is a small, early trial, and gabapentin may not reduce morphine use for everyone. It can also cause drowsiness, nausea, or vomiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
60 people
The number who actually took part.
- Started
-
Jan 2026
- Finished
-
Jun 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age between 18 to 60 years. 2. Female Gender 3. American Society of Anesthesiologists grade 1 and 2 patients. 4. Elective breast surgery 5. Admitted and day case surgeries Exclusion Criteria: 1. Patients allergic to gabapentin 2. Patients refusal. 3. Patients having a history of chronic pain. 4. Patients already using opioids for pain control
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shaukat Khanum Memorial Cancer Hospital and Research Centre
Lahore, Punjab Province, 5400, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Retrospective analysis of pyrotinib in the treatment of HER2-Positive advanced breast cancer previously treated with trastuzumab and pertuzumab
- Mind and body: does resilience leave a molecular mark in breast cancer?
- Which pain block works better for breast surgery?
- Can a Triple-Drug combo erase HER2-Positive breast tumors before surgery?
- Bacteria inside tumors may hold the key to breast cancer treatment
- Can a newer drug ease the bone pain of chemotherapy support?